Conference
Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Abstract
TPS5103
Authors
Beer TM; Blumenstein BA; Fizazi K; Hotte SJ; Jacobs C; Stewart PS
Volume
31
Pagination
pp. tps5103-tps5103
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.tps5103
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X